麦科奥特宣布与云顶新耀就全球首创双靶点多肽新药MT1013达成独家商业化合作
MICOT
点击蓝字 关注我们
Slide to view different languages
滑动查看不同语言
麦科奥特宣布与云顶新耀
就全球首创双靶点多肽新药MT1013
达成独家商业化合作
中国西安-2026年2月5日-陕西麦科奥特医药科技股份有限公司（以下简称“麦科奥特”），一家致力于成为双功能和多功能特异性多肽药物研发领军企业的创新型平台公司，今日宣布与云顶新耀（HKEX 1952.HK）达成独家商业化许可协议，授予云顶新耀MT1013注射剂在中国大陆、中国香港、中国澳门、中国台湾及除日本外的亚太区域，用于治疗继发性甲状旁腺功能亢进（SHPT）适应症的独家商业化权利。
根据协议，麦科奥特将获得人民币2亿元首付款，以及最高不超过人民币10.4亿元的潜在监管及商业里程碑款项，合计最高可达人民币12.4亿元。此次合作是麦科奥特核心管线下游价值实现的重要里程碑，标志着公司自主研发的全球首创双靶点多肽新药MT1013的商业化进程正式开启，并将借助合作伙伴成熟的商业化平台与肾病领域深耕经验，加速这一突破性疗法服务于全球市场。
MICOT
MT1013是由麦科奥特自主研发的全球首创、“First-in-Class”新一代双靶点多肽药物，2025年获美国肾脏病学会(ASN)年会“Late-Breaking”收录。其开创性地融合了“CaSR激动 + OGP（成骨生长肽）模拟”双重作用机制，解决了PTH、钙、磷代谢平衡的问题，首次创造性的从源头上控制病情，直接激活成骨通路，主动促进骨形成与修复，实现从“间接抑制骨吸收”到“主动促进骨生成”的治疗创新升级。临床研究数据证实，MT1013历史性的将SHPT的综合达标率（iPTH, 血钙，血磷均达标）提高到40%，较目前的综合治疗方案（CaSR激动+降磷剂+VD类药物）的达标率10%左右有了革命性的提高；低钙血症的发生率远低于依特卡肽（MT1013：依特卡肽，7%：15%），不良反应导致的停药率优于依特卡肽（安慰剂：MT1013：依特卡肽，18.8%：20.2%：30.3%），心血管获益指标FGF23显著优势（安慰剂：MT1013：依特卡肽，P=0.306：P=0.003：P=0.206）。目前，MT1013正在中国开展针对该患者群体的III期临床研究，入组已超过50%。
SHPT是慢性肾脏病（CKD）患者最常见的严重并发症之一。该疾病导致钙磷代谢紊乱、甲状旁腺激素升高、骨病变、血管钙化等一系列病理变化，显著增加骨折、心血管事件和死亡风险，是影响 CKD 患者预后的关键因素。随着全球慢性肾脏病患者规模持续扩大，SHPT 及其相关治疗需求亦不断增长。数据显示，全球CKD患者人数已由 2019 年的9.052亿人增至2024年的10.655 亿人，预计2030年将超12亿人，2035年将超15亿人；同期全球 SHPT 患者人数亦持续增长，预计2030年将达约1.899亿人，2035年将达约2.217亿人，临床需求亟待满足。
王冰博士
麦科奥特创始人、董事长王冰博士表示：“我们很高兴与云顶新耀达成此次战略合作。云顶新耀在肾病领域拥有深厚的市场积累和成熟的商业化体系，是推动MT1013惠及中国乃至全球患者的理想合作伙伴。MT1013是公司多肽技术平台的重要成果，代表着公司在慢病创新治疗领域深耕的重要里程碑达成，其独特的双靶点机制有望为SHPT治疗带来突破和更多获益。我们期待与云顶新耀紧密协作，加速该产品的临床开发和上市进程，共同满足广大未满足的临床需求，开启肾病领域治疗的全新篇章。”
吴以芳
云顶新耀董事会主席吴以芳表示：“我们非常高兴能与麦科奥特达成此次合作。在全球慢性肾脏病患者持续增加的背景下，继发性甲状旁腺功能亢进仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创新资产，有望为SHPT患者提供全新的治疗选择。作为潜在同类最佳药物，MT1013将与公司现有的肾科产品组合形成高度协同，进一步夯实公司在肾科领域的布局。云顶新耀在持续深耕自身免疫相关肾脏疾病的基础上，正加速拓展至肾小球肾炎以及慢性肾脏病及其并发症等更广泛的治疗领域。此次合作是公司完善创新管线、拓展肾科治疗边界的重要战略举措，标志着肾科战略由聚焦单一疾病领域向系统化和平台化的发展阶段升级。未来，双方将协同推进MT1013的开发与商业化，为更广泛的肾病患者提供创新治疗选择。”
关于MT1013：
ABOUT MT1013
MT1013是由陕西麦科奥特医药科技股份有限公司自主研发设计的作用于钙敏感受体（CaSR）且发挥成骨生长肽（OGP）作用的全球首款针对继发性甲旁亢合并肾性骨病的开创性双功能多肽治疗药物。其不仅强效抑制PTH分泌，更能直接促进骨形成，实现了从“单纯抑制”到“主动修复”的治疗升级。MT1013凭借其创新的双重机制，在SHPT治疗中展现出超越传统疗法的综合管理优势与骨改善潜力，它不仅有望为当前适应症提供“标本兼治”的新选择，还具备广阔的适应症拓展空间和全球商业化前景。
关于麦科奥特
ABOUT MICOT
陕西麦科奥特医药科技股份有限公司（以下简称“麦科奥特”）于2007年1月在西安成立，现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业，致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业，聚焦于心脑血管、代谢类疾病相关领域的新药研发。公司是是双特异性多肽概念的提出者、实施者、验证者和开发者，是多肽类药物研发的优秀平台之一，具有筛选多靶点多肽药物的特殊机制，具备开发First-in-class和Best-in-class品种的平台型研发能力，现已储备多个新药品种，其中进入临床研发的有7个原研创新药管线，包括1个临床三期阶段，3个临床二期阶段，3个临床一期阶段。公司致力于创制新药、挽救生命，满足未被满足的临床需求，用科技创新为人类健康保驾护航。更多信息，请访问公司官网：www.micot.cn
关于云顶新耀
ABOUT EVEREST MEDICINES
云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，致力于满足全球市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业拥有深厚的专长和丰富的经验。公司在浙江嘉善拥有具备商业化规模的全球生产基地，并严格按照国家药品监督管理局（NMPA）和欧洲药品管理局（EMA）的 GMP 要求及世界卫生组织（WHO）PQ 标准建设。公司聚焦自身免疫、眼科、急重症及CKM（心血管、肾脏及代谢）等疾病治疗领域，已打造集全渠道商业化体系与药品全生命周期商业化能力于一体的商业化平台，并以拥有全球权益的自研mRNA平台为基础，持续推进mRNA in vivo CAR-T与mRNA 肿瘤疫苗等现有管线，同时通过引进及生态孵化潜力平台，拓展研发能力，同时强化全球化布局，加快国际化发展进程。更多信息，请访问公司官网：www.everestmedicines.com
MICOT
欢迎关注
麦科奥特｜MICOT
Micot Announces Exclusive Commercialization Licensing Agreement with Everest Medicines to Commercialize MT1013
Xi'an, China – February 5, 2026 – Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”), an innovative platform company dedicated to becoming a global leader in the R&D of bifunctional and multifunctional specific peptide drugs, today announced an exclusive commercialization licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest"). The agreement grants Everest Medicines exclusive commercialization rights for the MT1013 in China and Asia-Pacific (excluding Japan) for the treatment of secondary hyperparathyroidism (SHPT).
According to the agreement, Micot will receive an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million, totaling a maximum of RMB 1.24 billion. This collaboration represents a significant milestone in the downstream value realization of Micot’s core pipeline. It marks the formal commencement of the commercialization process for MT1013, Micot's self-developed, global first-in-class dual-target peptide drug. By leveraging Everest’s established commercial platform and deep expertise in the nephrology field, this partnership aims to accelerate the delivery of this breakthrough therapy to the global market.
MICOT
MT1013 is the world’s first-in-class, new-generation dual-targeting peptide drug internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. The drug features a pioneering dual mechanism of action—“CaSR agonist + OGP (Osteogenic Growth Peptide) mimetic”—addressing the metabolic balance of PTH, calcium, and phosphorus. For the first time, it controls the disease at its source by directly activating osteogenic pathways and actively promoting bone formation and repair. This represents a therapeutic evolution from "indirectly inhibiting bone resorption" to "actively promoting bone formation." Clinical research data confirms that MT1013 has achieved a composite achievement rate (simultaneous control of iPTH, serum calcium, and serum phosphorus) of 40%, a revolutionary improvement over the approximately 10% achievement rate seen with current standard therapies (CaSR agonists + phosphate binders + Vitamin D analogs). The incidence of hypocalcemia was significantly lower than that of etelcalcetide (MT1013: etelcalcetide, 7% vs.15%). Discontinuation rates due to adverse events were superior to etelcalcetide (placebo: MT1013: etelcalcetide, 18.8%: 20.2%: 30.3%). Significant advantages were observed in FGF23, a key cardiovascular benefit indicator (placebo: MT1013: etelcalcetide, P=0.306: P=0.003: P=0.206). Currently, MT1013 is undergoing Phase III clinical trials in China for this patient population, with enrollment exceeding 50%.
SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.
Bing W
“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”
Yifang W
“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”
About MT1013
MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.
About Micot
Shaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.
As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.
Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.
The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com
MICOT
麦科奥特｜MICOT
详情
奋斗为本、求是创新、协作共赢
